# Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China

> **NCT04857164** · PHASE2 · RECRUITING · sponsor: **Yuankai Shi** · enrollment: 150 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab combined with Chemotherapy

## Key facts

- **NCT ID:** NCT04857164
- **Lead sponsor:** Yuankai Shi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-30
- **Primary completion:** 2023-08-20
- **Final completion:** 2026-01-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857164, "Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04857164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*